Please assess the completion status of the following clinical trial:

Trial Title: Calcium Electroporation for Treatment of Cutaneous Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Histological confirmed cutaneous metastases of any histology.~* At least 1. cutaneous metastases between 0,5 to 3cm, available to electroporation.~* Patient should have been offered standard treatment.~* At least 2 weeks since chemotherapy or radiotherapy.~* Performance status \>2 (ECOG).~* Life expectancy \>3 months.~* platelet count \> 50 mia/l.~* International Normalized Ratio (INR) \<1,2.~* Men and women of reproductive age must use effective contraception during the study.~* Patient should be able to understand participants information.~* Signed, informed consent.~Exclusion Criteria:~* Previously treatment with bleomycin \> 200.000 Units/m2.~* Allergy to bleomycin.~* Clinically significant coagulopathy.~* Pregnancy or lactation.~* Participation in other clinical trial involving experimental drugs or participation in a clinical trial within 4 weeks before study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Calcium electroporation (Type: EXPERIMENTAL): The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.~It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume.
- Electrochemotherapy with bleomycin (Type: ACTIVE_COMPARATOR): The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.~It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume.

Based on this trial design, predict the completion outcome and termination type (if applicable).